Figure 2.

The GAP‐f represents an opportunity to address challenges in paediatric drug formulation development. Challenges are grouped around three areas: dependence on adult drug development, paediatric formulation requirements and paediatric ARV market. Progress to‐date in addressing these challenges is depicted along a funnel originating from precursor mechanisms and leading up to the GAP‐f collaborative model. Legal framework challenges are placed outside of the funnel because of the limited influence of the GAP‐f to directly address these. PK, pharmacokinetic; GAP‐f, Global Accelerator for Paediatric Formulations; ARV, antiretroviral.